The following is a discussion of some feasible proposed pathways: Under different abiotic stress conditions, GSH (either alone or with H 2 O 2 or some other ROS) triggers adaptive or cell death processes through an intercellular signaling system (Foyer and Noctor 2005a, b)
Peptide therapy may be discussed for patients interested in tissue recovery, joint support, mobility, and post-exercise recovery
Additionally, it facilitates the infiltration of macrophages and fibroblasts, further emphasizing its therapeutic potential in managing wounds and accelerating the healing process of damaged tissues
doi: 10.1016/S0140-6736(18)31773-2
Most strikingly, approximately 60% of tirzepatide patients had achieved normal blood sugar levels after two years, compared to 24% in the control group
Documented mechanisms of action Preclinical studies (mostly Russian, to be reproduced in international protocols) report several mechanistic targets: BDNF increase (Brain-Derived Neurotrophic Factor) in the hippocampus and frontal cortex, measured by ELISA and Western blot 24-72 h post-administration Monoaminergic system modulation : cortical dopamine increase, serotonergic modulation Activation of the melanocortin pathway via MC4R receptors (residue shared with ACTH) Anti-oxidant and anti-apoptotic effect in cerebral ischaemia models (MCAO, middle cerebral artery occlusion) Experimental paradigms The most reported rodent models are the Morris water maze (spatial memory), novel object recognition (recognition memory), passive avoidance (aversive learning)
